116 related articles for article (PubMed ID: 35302484)
1. Oral Drugs Against COVID-19.
Mikus G; Foerster KI; Terstegen T; Vogt C; Said A; Schulz M; Haefeli WE
Dtsch Arztebl Int; 2022 Apr; 119(15):263-269. PubMed ID: 35302484
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
[TBL] [Abstract][Full Text] [Related]
4. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
5. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
[TBL] [Abstract][Full Text] [Related]
6. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.
Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K
J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to drug-drug interactions.
González-Gómez Á; Caro-Teller JM; González-Barrios I; Castro-Frontiñán A; Rodríguez-Quesada PP; Ferrari-Piquero JM
Farm Hosp; 2024; 48(2):70-74. PubMed ID: 37714801
[TBL] [Abstract][Full Text] [Related]
8. High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy.
Dong R; Huang Y; Ling X; Li L; Yu W; Jiang S
Int J Antimicrob Agents; 2024 Jan; 63(1):106997. PubMed ID: 37848106
[TBL] [Abstract][Full Text] [Related]
9. [Translated article] Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to DDIs.
González-Gómez Á; Caro-Teller JM; González-Barrios I; Castro-Frontiñán A; Rodríguez-Quesada PP; Ferrari-Piquero JM
Farm Hosp; 2024; 48(2):T70-T74. PubMed ID: 37953113
[TBL] [Abstract][Full Text] [Related]
10. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19.
Tomida T; Itohara K; Yamamoto K; Kimura T; Fujita K; Uda A; Kitahiro Y; Yokoyama N; Hyodo Y; Omura T; Yano I
Drug Metab Pharmacokinet; 2023 Dec; 53():100529. PubMed ID: 37924724
[TBL] [Abstract][Full Text] [Related]
11. Safely Prescribing Opioids With Nirmatrelvir/Ritonavir - Case Report and Management Recommendations.
Admane S; Clark M; Reddy A; Narayanan S; Bruera E
J Pain Symptom Manage; 2024 Jan; 67(1):e99-e104. PubMed ID: 37797677
[No Abstract] [Full Text] [Related]
12. A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.
Lo CM; Chen WH; Tsai MY; Lu HI; Hsiao YH; Chuang KH; Chen Y; Wu HF; Huang KT; Wang YH
J Cardiothorac Surg; 2024 Mar; 19(1):132. PubMed ID: 38491538
[TBL] [Abstract][Full Text] [Related]
13. Effect of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia.
Yii YC; Shih HM; Chen CL; Lai ZL; Hsu YL; Lai CH; Hsueh PR; Cho DY
Int J Antimicrob Agents; 2024 Jan; 63(1):107020. PubMed ID: 37898365
[TBL] [Abstract][Full Text] [Related]
14. Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study.
Butt AA; Yan P; Shaikh OS; Talisa VB; Omer SB; Mayr FB
J Infect Dis; 2024 Jan; 229(1):147-154. PubMed ID: 37711076
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
[TBL] [Abstract][Full Text] [Related]
16. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
[TBL] [Abstract][Full Text] [Related]
17. Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
Anderson AS; Caubel P; Rusnak JM;
N Engl J Med; 2022 Sep; 387(11):1047-1049. PubMed ID: 36069818
[No Abstract] [Full Text] [Related]
18. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.
Buchynskyi M; Oksenych V; Kamyshna I; Kamyshnyi O
Viruses; 2024 Jan; 16(1):. PubMed ID: 38257811
[TBL] [Abstract][Full Text] [Related]
19. Potential drug-drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross-sectional study of the National Covid Cohort Collaborative (N3C).
Xiao X; Mehta HB; Curran J; Garibaldi BT; Alexander GC;
Pharmacotherapy; 2023 Dec; 43(12):1251-1261. PubMed ID: 37539477
[TBL] [Abstract][Full Text] [Related]
20. Safely Prescribing Nirmatrelvir and Ritonavir-Avoiding Drug-Drug Interactions.
Culas R; Nath S; Nath S
JAMA Intern Med; 2023 Apr; 183(4):362-363. PubMed ID: 36807493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
